Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Hepatic Steatosis has no Impact on the Outcome of Treatment in Patients With Chronic Hepatitis B Infection

Cindoruk, Mehmet, MD; Karakan, Tarkan, MD; Unal, Selahattin, MD

Journal of Clinical Gastroenterology: May-June 2007 - Volume 41 - Issue 5 - p 513-517
doi: 10.1097/01.mcg.0000225586.78330.60
Liver, Pancreas and Biliary Tract: Clinical Research
Buy

Background Hepatic steatosis, as a predictive factor in treatment outcome, was not investigated in chronic hepatitis B (CHB). The aim of this retrospective analysis is to determine possible relationships between hepatic steatosis and treatment response in patients with CHB.

Methods One hundred forty patients with CHB [42 hepatitis B e antigen (HBeAg)-positive, 98 HBeAg-negative] were analyzed. Seventy-eight patients (55.7%) received pegylated interferon α 2a 180 μg/wk subcutaneously and 62 patients (44.3%) received pegylated interferon α 2a 180 μg/wk plus lamivudine 100 mg/d combination therapy.

Results The presence of steatosis was associated with increased body mass index and hyperlipidemia. The sustained virologic response (SVR) rates in HBeAg-negative patients were 36.2% and 31.5% in patients with and without steatosis, respectively (P>0.05). The SVR rates in HBeAg-positive patients were 39.6% and 33.3% in patients with and without steatosis, respectively (P>0.05). The prevalence of hepatic steatosis did not significantly affect the outcome of treatments in both groups. In pegylated interferon monotherapy group (group 1), SVR was 18/78 (23%) and in the pegylated interferon plus lamivudine combination group (group 2) SVR was 16/62 (26%), (P>0.05, NS). The independent factors affecting the treatment outcome were higher baseline alanine aminotransferase level and lower baseline viral load.

Conclusions The prevalence of steatosis is a common finding in CHB infection; however, it is not associated with viral load and treatment outcome.

Faculty of Medicine, Gastroenterology Department, Gazi University, Ankara, Turkey

Reprints: Dr Tarkan Karakan, MD, Faculty of Medicine, Gastroenterology Department, Gazi University, Ankara, Turkey (e-mail: tkarakan@gmail.com).

Received for publication April 6, 2006; accepted June 9, 2006

© 2007 Lippincott Williams & Wilkins, Inc.